100,000 Citizens Rally Against EU's Vaping Crackdown

Nov.22.2024
100,000 Citizens Rally Against EU's Vaping Crackdown
Over 100,000 citizens rally against the EU's proposed vaping restrictions, urging evidence-based policies to support harm reduction and consumer choice while highlighting Sweden's successful approach.

Brussels, Nov. 21, 2024.In a powerful display of consumer advocacy, the World Vapers' Alliance (WVA) today delivered over 100,000 signatures to the European Parliament, calling for a radical shift in the EU’s approach to vaping and harm reduction. The petition delivery was accompanied by a protest featuring a banner and symbolic delivery boxes from all 27 EU member states, highlighting the pan-European nature of this consumer movement.

 

While Sweden demonstrates the effectiveness of embracing harm reduction strategies, the EU is contemplating measures that could derail progress across the entire continent. Discussions around flavor bans, restrictions on nicotine pouches, outdoor vaping prohibitions, and increased taxation on reduced-risk products have sparked alarm among health advocates and consumers. These potential policies threaten to undermine years of advancement in tobacco harm reduction and could push millions of Europeans back towards more harmful traditional cigarettes.

 

Michael Landl, Director of the WVA, voiced his criticism of the EU’s current trajectory: “The EU’s misguided crusade against vaping and harm reduction is a public health disaster in the making. Flavour bans, outdoor vaping restrictions, and increased taxation will only drive people back to cigarettes. The EU must urgently shift its focus to evidence-based policies that actually save lives and empower consumers to quit smoking for good. The voices of 100,000 consumers demanding this change must not be ignored.”

 

The contrast between Sweden’s progressive approach and the EU’s regressive policies is stark. Sweden’s openness to harm reduction strategies has resulted in a smoking rate of just over 5%. Meanwhile, projections suggest the EU won’t reach its smoke-free goal until 2100 – a full 60 years behind schedule.

 

“Today’s action at the European Parliament is more than a petition delivery,” Landl added. “It’s a wake-up call. Each of these boxes represents thousands of voters from every corner of the EU who are saying ‘enough is enough’. We’re calling on MEPs to listen to their constituents and embrace policies that work.”

 

The WVA urges EU policymakers to prioritize consumer choice and public health by adopting evidence-based regulations that support safer alternatives to smoking. As discussions continue in Brussels, the alliance pledges to amplify the voices of vapers and harm reduction advocates across the continent.

 

Source: World Vapers' Alliance (WVA)

Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Nicotine analogues such as 6-methylnicotine are already appearing in e-cigarettes and oral pouches, even as key human evidence remains limited. A new Nixodine-S study adds nonclinical data showing differences from nicotine in cytotoxicity and receptor activity, while independent studies point to a more complex toxicological picture. With supply-chain activity growing and FDA seeking clearer authority over nicotine analogues, the industry now faces a larger question: what evidence is needed before these substances can credibly replace nicotine?
SCIENCE
Sep.23
Latest UK ONS Data: Vaping Rate Edges Down to 9.9% in 2025, a Year After Overtaking Cigarette Smoking
Latest UK ONS Data: Vaping Rate Edges Down to 9.9% in 2025, a Year After Overtaking Cigarette Smoking
Vaping prevalence in Great Britain edged down to 9.9% in 2025 from 10.0% in 2024, with the number of adult users holding at approximately 5.4 million for a second consecutive year, according to the Office for National Statistics (ONS). E-cigarette use had risen from 6.4% in 2020 to 10.0% in 2024, when it exceeded cigarette smoking prevalence for the first time. Cigarette smoking continued to decline to 8.7% in 2025, widening the gap to 1.2 percentage points. Daily vaping declined slightly, while usage among adults aged 25–34 increased despite falling rates in other age groups.
DATA
Oct.14
Why Does JPMorgan Favor BAT Over Philip Morris Despite Forecasting Slower Growth of 3.9% Versus 6.2%?
Why Does JPMorgan Favor BAT Over Philip Morris Despite Forecasting Slower Growth of 3.9% Versus 6.2%?
JPMorgan resumed equity research coverage of British American Tobacco (BAT), Philip Morris International (PMI) and Imperial Brands in November 2026, assigning BAT an Overweight rating and the other two companies Neutral ratings. The bank forecasts like-for-like sales growth of 3.9% for BAT and 6.2% for PMI in 2027, but estimates the two companies will trade at approximately 11 times and 21 times 2027 earnings, respectively. JPMorgan cited BAT's improving position in US nicotine pouches and vaping products as a driver of its investment outlook. BAT reported a 220% constant-currency increase in US modern oral nicotine revenue in the first half of 2026, while PMI's ZYN US shipments returned to growth in the third quarter. Imperial expects NGPs to represent 4% to 5% of sales and has expanded its oral portfolio through acquisitions.
Capital Markets
Nov.12
Snowplus Enters Japan’s FamilyMart Network With Zero-Nicotine NEO Line and Kishidan Campaign
Snowplus Enters Japan’s FamilyMart Network With Zero-Nicotine NEO Line and Kishidan Campaign
Snowplus distributor H&S said the zero-nicotine, zero-tar NEO vaping line will begin rolling out across FamilyMart stores in Japan from September 14, 2026, excluding some locations. The DASH line will also be sold at selected FamilyMart stores in southern Kyushu and Okinawa. Snowplus simultaneously named Japanese rock band Kishidan as a brand ambassador, combining convenience-store distribution with a broader consumer marketing push in Japan.
Sep.15
Texas Extends Tobacco Tax Interpretation to a 6-Methylnicotine Product, Citing VELO Ruling
Texas Extends Tobacco Tax Interpretation to a 6-Methylnicotine Product, Citing VELO Ruling
The Texas Comptroller of Public Accounts ruled in September 2026 that a combustible product made with non-tobacco plant material and 6-methylnicotine (6-MN), a synthetic nicotine analog, qualifies as a taxable tobacco product. The applicant said the product contained neither tobacco leaf nor measurable conventional nicotine. The determination applies reasoning from a May Texas Supreme Court decision involving VELO nicotine pouches, finding that the plant material and 6-MN together perform the functions of tobacco in a conventional smoking product. The ruling carries applicable tax, licensing and reporting obligations but is limited to the facts submitted by the taxpayer. It does not establish a blanket tax classification for all 6-MN products or extend the same conclusion to e-cigarettes.
Regulations
Nov.06